The estimated Net Worth of Jason Butch is at least $30.2 mil dollars as of 26 March 2021. Jason Butch owns over 10,000 units of Agile Therapeutics Inc stock worth over $30,200 and over the last 4 years he sold AGRX stock worth over $0.
Jason has made over 1 trades of the Agile Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of AGRX stock worth $20,100 on 26 March 2021.
The largest trade he's ever made was buying 10,000 units of Agile Therapeutics Inc stock on 26 March 2021 worth over $20,100. On average, Jason trades about 2,500 units every 0 days since 2021. As of 26 March 2021 he still owns at least 20,000 units of Agile Therapeutics Inc stock.
You can see the complete history of Jason Butch stock trades at the bottom of the page.
Jason Butch is the VP & Chief Accounting Officer at Agile Therapeutics Inc.
Jason's mailing address filed with the SEC is 500 COLLEGE ROAD EAST, SUITE 310, , PRINCETON, NJ, 08540.
Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor, eCapital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: